1. GENERAL INFORMATION
1.1 Each ml coffein-benzoate-sodium 10% and 20% solution contains respectively 0.1 g and 0.2 g coffein-benzoate-sodium.
1.2 The drug is sterile clear, colorless or pale yellow liquid, without visible inclusions.
1.3 The drug is available in glass vials by 10.0; 20.0 and 50.0 ml.
1.4 The drug should be stored according to list B in dry place, proteced from sunlight, away from children within the temperature range 0°C to +25°C. Shelf-life is 2 years from date of the drug production under specified storage conditions.
2. PHARMACOLOGICAL PROPERTIES
2.1. The drug stimulates central nervous system, especially cerebral cortex, medulla and spinal medulla to a lesser extent. The drug stimulates respiratory and vasomotor centers in the medulla, which leads to more frequent and deeper respiratory movements and increases pulmonary ventilation.
2.2. Under coffein-benzoate-sodium influence blood pressure is increased as a result of vasomotor center excitation and direct effect on heart. Under its influence blood vessels of abdominal organs and skin are narrowed and blood vessels of the heart, brain and kidneys are expanded, which also contributes to high blood pressure.
Coffein-benzoate-sodium stimulates heart and therefore absolute strength of heart contractions is increased and excitability of the heart muscle tissue is increased as well. Coffein increases water and nitrogen metabolism, eliminates acidosis, increases efficiency of striated muscle. It amplifies moving function of the gastrointestinal tract mainly due to excitation of the vagus nerve and improvement of metabolic processes.
2.3. During intoxication from coffein-benzoate-sodium such symptoms may be observed as heart disorders (decreased or increased heart pulse, arrhythmia), increased reflex excitability, colic-tonic convulsions, increased tone of skeletal muscles.
3. DRUG USAGE PROCEDURE
3.1. The drug is administered for excitation of central nervous system in various diseases of animals, accompanied by its oppression, loss of strength, muscle weakness, intoxication by poisons depressing nervous system (narcotics, sleeping pills).
The drug is prescribed against shock state, weakness of cardiovascular system, decreased excitability and conductivity in the heart; chronic myocarditis, muscular dystrophy, chronic myodegeneration; as a vasorelaxant – against vascular spasms in brain, kidneys and heart; for excitement of respiratory center and breathing improvement, during newborn asphyxia; milk fever; spastic muscle condition of the gastrointestinal tract.
3.2. The drug is administered subcutaneously, intramuscularly and intravenously. Depending on the disease severity and animal's weight, coffein-benzoate-sodium solution is administered in the following doses (approximately):
|Species||10% Solution||20% Solution|
|Horses||10-20 ml||5-10 ml|
|Cattle||10-20 ml||5-10 ml|
|Ruminants||1-4 ml||0,5-2 ml|
|Pigs||1-4 ml||0,5-2 ml|
|Dogs||0,4-1 ml||0,2-0,5 ml|
3.3. Side effects. Subcutaneous drug administration can lead to local edema induced by the coffein irritant effect. Disorders of the digestive tract may occur due to increased secretion of digestive glands. Anxiety, tachycardia, arrhythmia, and vomiting may be observed in case of overdose.
Individual sensitivity within the same species is clearly manifested against coffein-benzoate-sodium solution. Therefore dosage adjustment should be carried out taking into account individual properties of animal's nervous activity.
3.4. Contraindications. The drug is contraindicated in hyper excitability, uncompensated heart defects, myodegenerations, paralysis of peripheral vessels, congestive heart failure. 3.5. Animal products during and after treatment shall be used for food purposes without restrictions.
4. CLAIMS PROCEDURE
4.1. In case of inconsistency of the drug with requirements of this Instruction, its use should be discontinued and reported to the Uzbek State Scientific and Veterinary Drugs Control Laboratory at: 700178, Tashkent, No.1a, A.Yunusov Street. Tel. / Fax: 228-76-14, 229-30 - 47. E-mail: firstname.lastname@example.org. Simultaneously unpacked drug package should be sent to the laboratory address with the drug in quantity previously agreed with laboratory including detailed description of the nature of complaints regarding its inconsistency with this Instruction.